Article info
Inflammatory bowel disease
Original article
Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease
- Correspondence to Dr Sebastian Zeissig, Department of Medicine I, Universitätsklinikum Carl Gustav Carus Dresden, Technische Universität (TU) Dresden, Dresden 01307, Germany; sebastian.zeissig{at}tu-dresden.de and Dr Stefan Schreiber, Department of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany; s.schreiber{at}mucosa.de
Citation
Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease
Publication history
- Received January 13, 2018
- Revised April 3, 2018
- Accepted April 17, 2018
- First published May 5, 2018.
Online issue publication
June 15, 2020
Article Versions
- Previous version (15 June 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.